ATE273288T1 - 2,3,4,5-tetrahydro-1h-(1,4)benzodiazepin-3- hydroxamsäure als matrix metalloproteinaseinhibitoren - Google Patents

2,3,4,5-tetrahydro-1h-(1,4)benzodiazepin-3- hydroxamsäure als matrix metalloproteinaseinhibitoren

Info

Publication number
ATE273288T1
ATE273288T1 AT00909990T AT00909990T ATE273288T1 AT E273288 T1 ATE273288 T1 AT E273288T1 AT 00909990 T AT00909990 T AT 00909990T AT 00909990 T AT00909990 T AT 00909990T AT E273288 T1 ATE273288 T1 AT E273288T1
Authority
AT
Austria
Prior art keywords
benzodiazepine
tetrahydro
hydroxamic acid
matrix metalloproteinase
metalloproteinase inhibitors
Prior art date
Application number
AT00909990T
Other languages
English (en)
Inventor
Jay Donald Albright
Santos Efren Guillermo Delos
Jeremy Ian Levin
James Ming Chen
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of ATE273288T1 publication Critical patent/ATE273288T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
AT00909990T 1999-01-27 2000-01-27 2,3,4,5-tetrahydro-1h-(1,4)benzodiazepin-3- hydroxamsäure als matrix metalloproteinaseinhibitoren ATE273288T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23908099A 1999-01-27 1999-01-27
PCT/US2000/001991 WO2000044730A1 (en) 1999-01-27 2000-01-27 2,3,4,5-tetrahydro-1h-[1,4]benzodiazepine-3-hydroxamic acid as matrix metalloproteinase inhibitors

Publications (1)

Publication Number Publication Date
ATE273288T1 true ATE273288T1 (de) 2004-08-15

Family

ID=22900512

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00909990T ATE273288T1 (de) 1999-01-27 2000-01-27 2,3,4,5-tetrahydro-1h-(1,4)benzodiazepin-3- hydroxamsäure als matrix metalloproteinaseinhibitoren

Country Status (25)

Country Link
EP (1) EP1147095B1 (de)
JP (1) JP2002535392A (de)
KR (1) KR20010101730A (de)
CN (1) CN1197849C (de)
AR (1) AR022423A1 (de)
AT (1) ATE273288T1 (de)
AU (1) AU767039B2 (de)
BG (1) BG105736A (de)
BR (1) BR0007759A (de)
CA (1) CA2356267A1 (de)
CZ (1) CZ20012637A3 (de)
DE (1) DE60012883T2 (de)
EA (1) EA200100809A1 (de)
ES (1) ES2223470T3 (de)
HU (1) HUP0105302A3 (de)
ID (1) ID29046A (de)
IL (1) IL144168A0 (de)
NO (1) NO20013675L (de)
NZ (1) NZ511885A (de)
PL (1) PL349025A1 (de)
PT (1) PT1147095E (de)
SK (1) SK10422001A3 (de)
TR (1) TR200102131T2 (de)
WO (1) WO2000044730A1 (de)
ZA (1) ZA200104321B (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2357110A1 (en) * 2001-04-11 2002-10-11 American Cyanamid Company Method for the treatment of polycystic kidney disease
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
WO2003016248A2 (en) 2001-08-17 2003-02-27 Bristol-Myers Squibb Company Patent Department Bicyclic hydroxamates as inhibitors of matrix metalloproteinases and/or tnf-$g(a) converting enzyme (tace)
EP1440057A1 (de) 2001-11-01 2004-07-28 Wyeth Holdings Corporation Allenische arylsulfonamidhydroxamsäure als matrix-metalloproteinase und tace inhibitoren
US7488754B2 (en) 2002-04-05 2009-02-10 Wyeth Method for the treatment of polycystic kidney disease
JP2006501215A (ja) 2002-08-13 2006-01-12 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー マトリックスメタロプロテイナーゼ阻害剤としての単環式誘導体
AU2003304456A1 (en) 2002-12-23 2005-03-16 Wyeth Holdings Corporation Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors
US20040234699A1 (en) 2003-05-21 2004-11-25 Alexza Molecular Delivery Corporation Methods of controlling uniformity of substrate temperature and self-contained heating unit and drug-supply unit employing same
US7932389B2 (en) 2004-07-21 2011-04-26 Merck Serono S.A. Octahydropyrrolo[2,3C]pyridine derivatives and pharmaceutical use thereof
ATE509956T1 (de) * 2006-06-08 2011-06-15 Helmholtz Zentrum Muenchen Spezifische proteaseinhibitoren und ihre verwendung in der krebstherapie
EP1865001A1 (de) * 2006-06-08 2007-12-12 Gsf-Forschungszentrum Für Umwelt Und Gesundheit, Gmbh Spezifische Proteaseinhibitoren und ihre Verwendung in der Krebstherapie
US20080216828A1 (en) 2007-03-09 2008-09-11 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
FR2950057B1 (fr) 2009-09-17 2011-08-26 Galderma Res & Dev Nouveaux composes benzene-carboxylamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique
FR2950056B1 (fr) 2009-09-17 2011-08-26 Galderma Res & Dev Nouveaux composes benzene-carboxylamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique
ES2592154T3 (es) 2010-07-08 2016-11-28 Kaken Pharmaceutical Co., Ltd. Derivado de N-hidroxiformamida y medicamento que contiene el mismo
CN103189501B (zh) * 2010-09-17 2015-04-22 国立大学法人东京大学 用于维持血小板的功能的组合物
AU2019352741A1 (en) 2018-10-04 2021-05-06 Assistance Publique-Hôpitaux De Paris (Aphp) EGFR inhibitors for treating keratodermas
US20220370463A1 (en) * 2019-09-19 2022-11-24 New York Society for the Relief of the Ruptured and Crippled, Maintaining the Hospital for Special S Stabilized c-fms intracellular fragments (ficd) promote osteoclast differentiation and arthritic bone erosion

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
WO1996033172A1 (en) * 1995-04-20 1996-10-24 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives as mmp and tnf inhibitors
CN1131215C (zh) * 1995-11-13 2003-12-17 赫彻斯特股份公司 环和杂环N－取代的α－亚氨基异羟肟酸和羧酸
AU725831C (en) * 1995-12-08 2002-10-17 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation
US5753653A (en) * 1995-12-08 1998-05-19 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
DK0923561T3 (da) * 1996-08-28 2003-02-24 Procter & Gamble Heterocykliske metalloproteaseinhibitorer
NZ334252A (en) * 1996-08-28 2000-11-24 Procter & Gamble Heterocyclic metalloprotease inhibitors
DE69716934T2 (de) * 1996-08-28 2003-07-31 Procter & Gamble 1,3-diheterozyklische metalloprotease inhibitoren
PL342045A1 (en) * 1998-01-27 2001-05-21 American Cyanamid Co 2,3,4,5-tetrahydro-1h-[1,4]-benzdiazepin-3-hydroxamic acids as inhibitors of matrix metaloproteinases

Also Published As

Publication number Publication date
HUP0105302A3 (en) 2002-09-30
EA200100809A1 (ru) 2002-02-28
BG105736A (en) 2002-05-31
WO2000044730A1 (en) 2000-08-03
ID29046A (id) 2001-07-26
NO20013675D0 (no) 2001-07-26
SK10422001A3 (sk) 2002-09-10
PT1147095E (pt) 2004-12-31
CN1197849C (zh) 2005-04-20
IL144168A0 (en) 2002-05-23
NZ511885A (en) 2003-06-30
ZA200104321B (en) 2002-08-26
AR022423A1 (es) 2002-09-04
EP1147095A1 (de) 2001-10-24
AU3216000A (en) 2000-08-18
DE60012883D1 (de) 2004-09-16
ES2223470T3 (es) 2005-03-01
PL349025A1 (en) 2002-07-01
TR200102131T2 (tr) 2001-12-21
CA2356267A1 (en) 2000-08-03
BR0007759A (pt) 2001-11-13
CN1337952A (zh) 2002-02-27
DE60012883T2 (de) 2005-08-25
AU767039B2 (en) 2003-10-30
EP1147095B1 (de) 2004-08-11
JP2002535392A (ja) 2002-10-22
NO20013675L (no) 2001-09-21
HUP0105302A2 (hu) 2002-07-29
CZ20012637A3 (cs) 2002-04-17
KR20010101730A (ko) 2001-11-14

Similar Documents

Publication Publication Date Title
ATE257151T1 (de) Hydroxamsäure-derivate als matrix metalloproteinaseinhibitoren
EE200000720A (et) Uus 3-arüül-2-hüdroksüpropaanhappe derivaat (I)
ATE273288T1 (de) 2,3,4,5-tetrahydro-1h-(1,4)benzodiazepin-3- hydroxamsäure als matrix metalloproteinaseinhibitoren
EE200200069A (et) Metalloproteinaaside inhibiitoriteks olevad pürimidiin-3,4,6-trioonid
DK1181017T3 (da) Metalloproteaseinhibitorer
EE200000717A (et) Uus 3-arüül-2-hüdroksüpropaanhappe derivaat III
DE60009675D1 (de) Protonenpumpinhibitoren enthaltende zusammensetzung
DE60008548D1 (de) Hydroxamsäurederivate als matrix-metalloproteinase-inhibitoren
NO20014243L (no) Dihetero-substituerte metalloproteaseinhibitorer
ATE309220T1 (de) Substituierte 1,2,3,4-tetrahydrochinolin-2- carbonsäurederivate
EE9900180A (et) Asendatud 4-bifenüül-4-hüdroksübutaanhappe derivaadid metalloproteaasimaatriksi inhibiitoritena
ATE271541T1 (de) Alkinylische hydroxamsäureverbindungen als tace inhibitoren
DK1047665T3 (da) Matrix metalloprotease inhibitorer
NO20003828D0 (no) 2,3,4,5-Tetrahydro-1H-[1,4]-benzodiazepin-3-hydroksamsyrer som matriks-metalloproteinaseinhibitorer
GB9916562D0 (en) 3-Arylsulfonyl-2-(substituted-methyl) propanoic acid derivatives as matrix metalloproteinase inhibitora
PL357084A1 (en) Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors
ATE205822T1 (de) Substituierte 4-arylbutyrsäurederivate als matrix metalloprotease inhibitoren
ATE323673T1 (de) Pyrrolidin-2-carbonsäure-hydrazid-derivate als metalloprotease-inhibitoren
ATE227288T1 (de) Acetylenische ortho-sulfonamido- und phosphinsäure-amido-bicyclische heteroarylhydroxamsäure als tace-inhibitoren
DK1147095T3 (da) 2,3,4,5-Tetrahydro-1H-[1,4]benzodiazepin-3-hydroxamsyrer som matrixmetalloproteinaseinhibitorer
DE60017150D1 (de) 1,4,5,6 -tetrahydropyrimidine-derivative als vitronectin-hemmer
IT1308231B1 (it) Blocco antisismico.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1147095

Country of ref document: EP

REN Ceased due to non-payment of the annual fee